3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid chloride | 924635-09-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid chloride
• 英文别名: 3-Hydroxy-8-(trifluoromethyl)quinoline-4-carbonyl chloride；3-hydroxy-8-(trifluoromethyl)quinoline-4-carbonyl chloride
• CAS: 924635-09-6
• 化学式: C₁₁H₅ClF₃NO₂
• 分子量: 275.614
• InChiKey: RTBPSHJUJSWDDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid chloride 在 palladium diacetate 、 2-(二环己基膦基)联苯 sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 caesium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 、 叔丁醇 为溶剂， 反应 23.0h， 生成 2-(4-Chlorophenylamino)-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid
  参考文献：
  名称：

  2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic Acid (PSI-697):  Identification of a Clinical Candidate from the Quinoline Salicylic Acid Series of P-Selectin Antagonists

  摘要：

  P-selectin-PSGL-1 interaction causes rolling of leukocytes on the endothelial cell surface, which subsequently leads to firm adherence and leukocyte transmigration through the vessel wall into the surrounding tissues. P-selectin is upregulated on the surface of both platelets and endothelium in a variety of atherosclerosis-associated conditions. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of atherosclerosis. High-throughput screening and subsequent analoging had led to the identification of compound 1 as the lead candidate. Herein, we report the continuation of this work and the discovery of a second-generation series, the tetrahydrobenzoquinoline salicylic acids. These compounds have improved pharmacokinetic properties, and a number of them have shown oral efficacy in mouse and rat models of atherogenesis and vascular injury. The lead 31 (PSI-697), is currently in clinical development for the treatment of atherothrombotic vascular events.

  DOI：

  10.1021/jm060631p
• 作为产物：
  描述：

  邻氨基三氟甲苯 在 盐酸 、 氢氧化钾 、 草酰氯 、 硫酸 、 盐酸羟胺 、 sodium sulfate 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid chloride
  参考文献：
  名称：

  2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic Acid (PSI-697):  Identification of a Clinical Candidate from the Quinoline Salicylic Acid Series of P-Selectin Antagonists

  摘要：

  P-selectin-PSGL-1 interaction causes rolling of leukocytes on the endothelial cell surface, which subsequently leads to firm adherence and leukocyte transmigration through the vessel wall into the surrounding tissues. P-selectin is upregulated on the surface of both platelets and endothelium in a variety of atherosclerosis-associated conditions. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of atherosclerosis. High-throughput screening and subsequent analoging had led to the identification of compound 1 as the lead candidate. Herein, we report the continuation of this work and the discovery of a second-generation series, the tetrahydrobenzoquinoline salicylic acids. These compounds have improved pharmacokinetic properties, and a number of them have shown oral efficacy in mouse and rat models of atherogenesis and vascular injury. The lead 31 (PSI-697), is currently in clinical development for the treatment of atherothrombotic vascular events.

  DOI：

  10.1021/jm060631p